Antonio Chella

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

Enriqueta Felip, Nasser K. Altorki, Caicun Zhou et al. · The Lancet · 2021 · 1.5K citations

Medicine, Oncology, Pharmacology +13

<i>EGFR</i> Mutations in Non–Small-Cell Lung Cancer: Analysis of a Large Series of Cases and Development of a Rapid and Sensitive Method for Diagnostic Screening With Potential Implications on Pharmacologic Treatment

Antonio Marchetti, Carla Martella, Lara Felicioni et al. · Journal of Clinical Oncology · 2005 · 793 citations

Medicine, Genetics, Oncology +17

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients

Armida D’Incecco, Mariacarla Andreozzi, Vienna Ludovini et al. · British Journal of Cancer · 2014 · 605 citations · Full text

Medicine, Oncology, Pharmacology +17

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim et al. · The Lancet Oncology · 2018 · 576 citations · Full text

Medicine, Oncology, Pharmacology +8

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring <i>BRAF</i> Mutations

Antonio Marchetti, Lara Felicioni, Sara Malatesta et al. · Journal of Clinical Oncology · 2011 · 561 citations

Medicine, Genetics, Oncology +17